The findings by researchers from the Centre for Nanoscale BioPhotonics (CNBP) in Australia are based on the successful quantification of singlet oxygen produced during photodynamic therapy for cancer.
Singlet oxygen molecules (a highly reactive form of oxygen) are able to kill or inhibit growth of cancer cells in the body due to their toxicity.
"Photodynamic therapy is where light sensitive compounds are placed near diseased cells, then activated by light, producing short lived molecular by-products that can destroy or damage the cells being targeted," said Ewa Goldys from CNBP.
The findings are significant as this is the first time that anyone has been able to quantify accurately, the number of singlet oxygen molecules produced in this type of procedure, researchers said.
"Singlet oxygen molecules are a far more reactive form of oxygen but they can only kill cancer cells if generated in sufficient quantity," said Goldys.
Photodynamic therapy has traditionally utilised near-infrared or visible light which has been unable to penetrate far into the body, limiting its use to cancer treatment, on or near the surface of the skin, Goldys said.
The treatment uses different biological pathways to kill cells as compared to chemotherapy, radiotherapy and other current cancer practices.
"We are looking to target cancer cells deeper in the body hence the use of X-rays, which can really penetrate into deeper levels of tissue, and are already used in medical diagnostic and therapy," Goldys said.
Deep tissue photodynamic therapy will potentially provide new treatment options for the cancer patients of the future, researchers said.
The findings were published in the journal Scientific Reports.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
